Core Insights - Aligos Therapeutics, Inc. announced six presentations at the 2025 International HBV Meeting, highlighting its commitment to advancing therapies for liver and viral diseases [1][2][3] Group 1: Presentations Overview - The presentations include three oral presentations and cover topics such as novel approaches and molecular strategies for treating hepatitis B and delta virus infections [2][3] - The Phase 2 B-Supreme study is progressing well, with new data showing the effects of ALG-000184 in reducing HBV cccDNA in preclinical settings [3] - The company is also focusing on a proprietary antisense oligonucleotide (ASO) approach aimed at potentially curing hepatitis delta virus (HDV) infection [2][3] Group 2: Specific Presentation Details - Oral Presentation 52: "The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments" presented by Yannick Debing on September 11, 2025 [3][4] - Oral Presentation 53: "Antisense oligonucleotide-based strategy to target hepatitis delta virus infections" presented by Julie Lucifora on September 11, 2025 [3][4] - Oral Presentation 2: "A Syrian hamster model of persistent HDV infection" presented by Elias Broeckhoven on September 8, 2025 [3][4] Group 3: Company Background - Aligos Therapeutics is a clinical stage biotechnology company focused on developing best-in-class therapies for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and metabolic dysfunction-associated steatohepatitis (MASH) [5]